Form 4: Recursion Pharma Exec Acquires Shares, Options

Najat Khan, Chief R&D Commercial Officer of Recursion Pharmaceuticals, acquired 84,925 Class A Common Stock units and 169,851 stock options under a pre-arranged plan.

Summary

• Najat Khan, a Director and Chief R&D Commercial Officer at Recursion Pharmaceuticals, Inc. (RXRX), acquired 84,925 shares of Class A Common Stock and 169,851 stock options.
• The transactions occurred on November 5, 2025, and were made pursuant to a Rule 10b5-1(c) plan.
• The 84,925 Class A Common Stock units are Restricted Stock Units (RSUs) that will vest in 1/16th increments starting February 15, 2026, and every three months thereafter.
• The 169,851 stock options have an exercise price of $4.96 and will vest in 1/48th increments starting December 5, 2025, and monthly thereafter, expiring on November 5, 2035.
• Following these transactions, Khan beneficially owns 753,122 Class A Common Stock shares and 169,851 stock options directly.

Sentiment

Score: 7

Explanation: The acquisition of a significant number of shares and options by a key executive, particularly under a 10b5-1 plan, generally indicates management's confidence in the company's future prospects. This is a positive signal for investors, although it represents compensation rather than an open market purchase.

Positives

• Significant acquisition of equity and derivative securities by a key executive, indicating confidence in the company's future.
• The transactions were executed under a Rule 10b5-1 plan, suggesting a pre-planned, long-term investment strategy.
• The stock options have an exercise price of $4.96, which could incentivize the executive to drive share price appreciation.

Negatives

• No direct negatives identified in this Form 4 filing, as it reports an acquisition of securities.

Future Outlook

The filing indicates future vesting schedules for both the acquired Restricted Stock Units and stock options, extending into 2026 and beyond, suggesting a long-term incentive structure for the executive.

Industry Context

Insider acquisitions, particularly by key R&D and commercial officers in biotechnology firms like Recursion Pharmaceuticals, can signal internal confidence in the company's drug pipeline, research progress, or commercialization strategy. This is especially relevant in a sector where long-term development cycles and regulatory approvals are critical.

Comparison to Industry Standards

• The grant of RSUs and stock options as part of executive compensation is a standard practice across the biotechnology and pharmaceutical industries, aligning executive incentives with shareholder value creation.
• The specific vesting schedules (e.g., 1/16th quarterly for RSUs, 1/48th monthly for options) are typical for long-term incentive plans designed to retain talent and encourage sustained performance over several years.
• The exercise price of $4.96 for the options provides a clear benchmark for future stock performance relative to the grant date.

Related Party Transactions

• The acquisition of 84,925 Class A Common Stock units and 169,851 stock options by Najat Khan, a Director and Chief R&D Commercial Officer, constitutes a related party transaction as it involves an executive of the company.

Stakeholder Impact

• Shareholders: The acquisition by a key executive could be viewed positively, signaling internal confidence and potentially aligning executive interests with shareholder value.
• Employees: The compensation structure, including RSUs and stock options, reflects the company's approach to incentivizing and retaining key talent.

Next Steps

• The 84,925 Restricted Stock Units will begin vesting on February 15, 2026, with subsequent vesting every three months thereafter.
• The 169,851 stock options will begin vesting on December 5, 2025, with subsequent vesting occurring monthly thereafter until fully vested.

Key Dates

Recommendation

While insider acquisitions are generally positive signals, this Form 4 primarily reports a compensation grant rather than an open market purchase. The long-term vesting schedules align executive interests with future performance, which is a good governance practice. However, without additional financial or operational updates, this filing alone does not warrant a "buy" recommendation, but rather reinforces a "hold" for existing investors, pending further fundamental analysis.

Keywords

Recursion Pharmaceuticals, RXRX, Insider Trading, Form 4, Stock Options, Restricted Stock Units, Executive Compensation, Biotechnology, Pharmaceuticals, Najat Khan, 10b5-1 Plan